Richard Heard, MD
Gastroenterology · Columbus, MSNPI 1508029380
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.3% of the total across 459 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 23.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,787, 3.2 times the $557 reported in 2019.
Across 459 payments — averaging $16.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Johnson & Johnson$1K
- Takeda Pharmaceuticals U.S.A., Inc.$683
- Sanofi$640
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$637
- Gilead$489
- plus $2K from 22 others
What the payments were for
- Food & beverage$7,27196%
- Education$2814%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 137 | $1,806 |
| Johnson & Johnson | 62 | $1,183 |
| Takeda Pharmaceuticals U.S.A., Inc. | 39 | $683 |
| Sanofi | 27 | $640 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 43 | $637 |
| Gilead | 26 | $489 |
| Ardelyx, Inc. | 14 | $290 |
| Aimmune Therapeutics, Inc. | 13 | $205 |
| Madrigal Pharmaceuticals | 11 | $197 |
| QOL Medical, LLC | 8 | $168 |
| Merck | 11 | $155 |
| Pfizer | 10 | $155 |
| Bristol Myers Squibb | 10 | $150 |
| Intercept Pharmaceuticals, Inc. | 9 | $129 |
| Lilly USA, LLC | 7 | $121 |
| Regeneron Healthcare Solutions, Inc. | 4 | $104 |
| Ironwood Pharmaceuticals, Inc | 6 | $101 |
| Redhill Biopharma Inc. | 6 | $86 |
| Phathom Pharmaceuticals, Inc. | 3 | $45 |
| Nestle Healthcare Nutrition Inc. | 3 | $45 |
| Braintree Laboratories, Inc. | 3 | $37 |
| Mauna Kea Technologies, Inc. | 1 | $24 |
| Bayer | 1 | $22 |
| Ferring Pharmaceuticals Inc. | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Novo Nordisk | 1 | $15 |
| Celltrion USA Inc. | 1 | $14 |
| Alfasigma USA, Inc. | 1 | $13 |
How this compares
$7,552 in reported general payments places this provider in the 65th percentile of 127 gastroenterology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 30 | $98,764 |
| LinzessLinaclotide | 82 | $78,330 |
| ZenpepLipase/Protease/Amylase | 13 | $49,311 |
| Mesalamine | 27 | $10,735 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 162 | $10,571 |
| Dexlansoprazole DrDexlansoprazole | 33 | $10,505 |
| Colestipol Hcl | 68 | $4,826 |
| Lubiprostone | 11 | $3,947 |
| Omeprazole | 239 | $2,082 |
| Pantoprazole Sodium | 225 | $2,062 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 98 | $1,487 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 97 | $1,391 |
| Esomeprazole Magnesium | 35 | $1,385 |
| Famotidine | 121 | $1,176 |
| Lansoprazole | 32 | $747 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $1,806 | $177,094112 claims |
| Aimmune Therapeutics, Inc.Zenpep | $205 | $49,31113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 127 gastroenterology providers in Mississippi.
Other gastroenterology in Columbus
- Richard JohnstonColumbus$8K
- Samuel JohnsonColumbus$8K
- Alan WilliamsColumbus$5K
- Wassem JuakiemBiloxi$519K
- Reed HoganFlowood$216K
- John PhillipsTupelo$150K
- Brian BorgJackson$68K
- Pegah Hosseini-CarrollJackson$62K
- Shou Jiang TangJackson$50K
- Vonda ReevesFlowood$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.